retatrutide expanded access compassionate use eli lilly stock jumps on Phase 3 weight loss results A Study of Retatrutide (LY3437943)

3.2.2 Passive Diffusion Across Cell Membranes Due to the significant improvement in lipophilicity, SAG can cross cell membranes via passive diffusion

Overall, the results of this study indicate that LY3437943 has a safety and tolerability profile similar to other incretins, with pharmacokinetic and pharmacodynamic outcomes that support further clinical evaluation

Unika Salk Bilimleri Dergisi 1 (2), 101117 (2021) F

Dupixent remained the companys standout product, generating $10.7 billion in sales during the first half of the year and continuing to drive overall growth Q1: Which pharma company had the highest Q1 2026 revenue